Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.32 |
| ▸ | THRA | P10827 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2118677 | 0.82 | DHFR (0.42) | BACE1DHFRGABRA1GABRB2BCHE | |
| SCHEMBL9734907 | 0.82 | CNR1 (0.48) | BACE1DHFRCNR1CNR2GPR84 | |
| SCHEMBL31174278 | 0.82 | BACE1 (0.68) | BACE1GABRA1GABRB2CNR1CNR2 | |
| SCHEMBL7460854 | 0.81 | CNR1 (0.39) | BACE1TDP1MEN1KMT2AGABRA1 | |
| SCHEMBL10799332 | 0.79 | TDP1 (0.44) | BACE1TDP1MEN1KMT2A | |
| SCHEMBL444673 | 0.79 | TRPA1 (0.48) | BACE1DHFRAKT1TAAR1 | |
| SCHEMBL3847706 | 0.78 | BACE1 (0.69) | BACE1DHFRTDP1TAAR1CYP3A4 | |
| SCHEMBL12441747 | 0.78 | BACE1 (0.44) | BACE1DHFRAKT1CNR1CNR2 | |
| SCHEMBL10193342 | 0.78 | BACE1 (0.44) | BACE1DHFRAKT1GABRA1GABRB2 | |
| SCHEMBL9734644 | 0.78 | SKP2 (0.50) | BACE1SKP2GPR84THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7320982-B2 | Use of 4-substituted tetrahydropyridines for the manufacture of medicaments acting upon TGF-β 1 | SANOFI-AVENTIS (FR) | 2008-01-22 | — | — | US | disclosed |
| CN-1708492-A | Selected CGRP antagonists, method for production and use thereof as medicament | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-12-14 | — | — | CN | disclosed |
| US-20040157868-A1 | Use of 4-substituted tetrahydropyridines for the manufacture of medicaments acting upon TGF-beta 1 | SANOFI-AVENTIS (FR) | 2004-08-12 | — | — | US | disclosed |
| EP-0979079-B1 | USE OF TETRAHYDROPYRIDINE DERIVATIVES TO PREPARE MEDICINES FOR TREATING DISEASES CAUSING DEMYELINATION | SANOFI SYNTHELABO (FR) | 2004-06-16 | — | — | EP | disclosed |
| US-6693118-B2 | E.G., 1-(2-(6,7-METHYLENEDIOXYNAPHTH-2-YL)-ETHYL)-4-(3-TRIFLUOROMETHYLPHENYL)-1,2,3,6-TETRAHYDROPYRIDINE AND 1-2-(4-CYCLOHEXENYLPHENYL)-ETHYL)-4-(3-TRIFLUOROMETHYLPHENYL)-1,2,3,6 -TETRAHYDROPYRIDINE; apoptosis inhibition; treatment of graft rejection or of acute or chronic rheumatoid arthritis | SANOFI-SYNTHELABO (FR) | 2004-02-17 | — | — | US | disclosed |
| EP-1017385-B1 | USE OF 4-SUBSTITUTED TETRAHYDROPYRIDINES FOR MAKING MEDICINES ACTING ON TGF-beta 1 | SANOFI SYNTHELABO (FR) | 2003-07-16 | — | — | EP | disclosed |
| US-20020091143-A1 | Use of 4-substituted tetrahydropyridines for the manufacture of medicament s acting upon TGF-beta 1 | SANOFI-AVENTIS (FR) | 2002-07-11 | — | — | US | disclosed |
| EP-0950048-B1 | 1-PHENYLALKYL-1,2,3,6-TETRAHYDROPYRIDINES FOR TREATING ALZHEIMER'S DISEASE | SANOFI SYNTHELABO (FR) | 2001-06-27 | — | — | EP | disclosed |
| EP-1017385-A1 | USE OF 4-SUBSTITUTED TETRAHYDROPYRIDINES FOR MAKING MEDICINES ACTING ON TGF-beta 1 | SANOFI-SYNTHELABO (FR) | 2000-07-12 | — | — | EP | disclosed |
| EP-0979079-A1 | USE OF TETRAHYDROPYRIDINE DERIVATIVES TO PREPARE MEDICINES FOR TREATING DISEASES CAUSING DEMYELINATION | SANOFI-SYNTHELABO (FR) | 2000-02-16 | — | — | EP | disclosed |
| EP-0950048-A1 | 1-PHENYLALKYL-1,2,3,6-TETRAHYDROPYRIDINES FOR TREATING ALZHEIMER'S DISEASE | SANOFI-SYNTHELABO (FR) | 1999-10-20 | — | — | EP | disclosed |
| WO-1998053821-A1 | USE OF 4-SUBSTITUTED TETRAHYDROPYRIDINES FOR MAKING MEDICINES ACTING ON TGF-β1 | SANOFI-SYNTHELABO (FR) | 1998-12-03 | — | — | WO | disclosed |
| WO-1998048802-A1 | USE OF TETRAHYDROPYRIDINE DERIVATIVES TO PREPARE MEDICINES FOR TREATING DISEASES CAUSING DEMYELINATION | SANOFI-SYNTHELABO (FR) | 1998-11-05 | — | — | WO | disclosed |
| WO-1998025903-A1 | 1-PHENYLALKYL-1,2,3,6-TETRAHYDROPYRIDINES FOR TREATING ALZHEIMER'S DISEASE | SANOFI (FR) | 1998-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091143-A1 | Use of 4-substituted tetrahydropyridines for the manufacture of medicament s acting upon TGF-beta 1 | TGFB1, TGFBR1, TGFB2 | BACE1 90/4885DHFR 734/4885TDP1 1421/4885 |
| US-20040157868-A1 | Use of 4-substituted tetrahydropyridines for the manufacture of medicaments acting upon TGF-beta 1 | TGFB1, TGFBR1, TGFB2 | BACE1 134/4885DHFR 663/4885TDP1 1461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.